On July 22, CMBC CAPITAL rose 5.3% in regular trading, trading at HKD 4.57 per share, with turnover of HKD 318 million. The stock staged a notable rebound following the prior session's 17.3% plunge to HKD 4.11.

The previous day's sharp selloff was triggered by the lapse of the IPO prospectus of Beijing PuQi Pharma, for which CMBC CAPITAL served as joint sponsor, combined with sustained southbound capital outflows. Market commentary noted that the single prospectus lapse does not alter the company's broader investment banking expansion trajectory, as its sponsorship business has landed multiple mandates across TMT and healthcare sectors this year.

Fundamentally, the company reported annual net profit of HKD 151 million, representing a 197.73% year-over-year increase, driven primarily by a significant rise in securities underwriting and sponsorship fee income. The improved earnings profile provides valuation support for the technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)